|
KMID : 0624620210540080403
|
|
BMB Reports
2021 Volume.54 No. 8 p.403 ~ p.412
|
|
|
Perspectives on immune checkpoint ligands: expression, regulation, and clinical implications
|
|
Moon Ji-Hyun
Oh Yoo-Min
Ha Sang-Jun
|
|
|
Abstract
|
|
|
|
In the tumor microenvironment, immune checkpoint ligands (ICLs) must be expressed in order to trigger the inhibitory signal via immune checkpoint receptors (ICRs). Although ICL expression frequently occurs in a manner intrinsic to tumor cells, extrinsic factors derived from the tumor microenvironment can fine-tune ICL expression by tumor cells or prompt non-tumor cells, including immune cells. Considering the extensive interaction between T cells and other immune cells within the tumor microenvironment, ICL expression on immune cells can be as significant as that of ICLs on tumor cells in promoting antitumor immune responses. Here, we introduce various regulators known to induce or suppress ICL expression in either tumor cells or immune cells, and concise mechanisms relevant to their induction. Finally, we focus on the clinical significance of understanding the mechanisms of ICLs for an optimized immunotherapy for individual cancer patients.
|
|
|
KEYWORD
|
|
|
Immune checkpoint ligand, Immune checkpoint receptor, Immunotherapy, Tumor microenvironment
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|